AB Science expects negative opinion on masitinib application in Europe
An advisory committee of the European Medicines Agency (EMA) is leaning against recommending the conditional approval of AB Science’s…
Articles by Margarida Maia, PhD
Clene expanding CNM-Au8 expanded access program in US
Clene Nanomedicine has nearly doubled the enrollment cap for a soon-to-launch expanded access program (EAP) to allow more patients…
Patient guide aims to increase, diversify clinical trial participation
The Les Turner ALS Foundation, in an effort to boost and diversify clinical trial participation, has written a step-by-step…
Extended treatment with NurOwn may offer additional benefits in ALS
People with amyotrophic lateral sclerosis (ALS) who continued treatment with NurOwn (debamestrocel) after completing a Phase 3 trial…
NeuroSense taps machine learning to optimize PrimeC Phase 3 testing
NeuroSense Therapeutics is collaborating with PhaseV for insights into how to better design the protocol for the planned…
Tambourine awards $5M to eight research projects into ALS
The Tambourine ALS Breakthrough Research Fund has committed more than $5 million in funding to eight research projects aiming to…
ALS women live longer than men despite faster functional decline
While women with amyotrophic lateral sclerosis (ALS) see a faster functional decline, men have shorter survival times, mostly due…
Certain spinal fluid biomarkers may predict responses to NurOwn
Treatment with NurOwn (debamestrocel), which BrainStorm Cell Therapeutics is developing for amyotrophic lateral sclerosis (ALS), may bring about changes in…
ALS Society-Brain Canada grant aids work into protein clumping in ALS
Researchers at the University of Waterloo will use a CA$125,000 (about $93,000) grant from the ALS Society of Canada…
Dewpoint wins grant to develop its condensate-modifying therapies
Dewpoint Therapeutics has received a grant from the Target ALS Foundation to advance the development of small molecules…